Liminal BioSciences  logo
Liminal BioSciences LMNL
report update icon

Quarterly report 2023-Q2
added 05-23-2026

Liminal BioSciences Market Cap | LMNL

As of September 14, 2026 Liminal BioSciences has a market cap of $ 256 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Liminal BioSciences

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- 2.65 M 11.7 M 133 M 248 M 876 M 971 M 1.03 B 867 M 612 M 130 K -

All numbers in CAD currency

Indicator range from annual reports

Maximum Minimum Average
1.03 B 130 K 475 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
Aclaris Therapeutics Aclaris Therapeutics
ACRS
385 M $ 5.65 6.11 % $ 692 M usaUSA
Фармсинтез Фармсинтез
LIFE
2 B - - - russiaRussia
AbbVie AbbVie
ABBV
400 B $ 261.61 1.7 % $ 463 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
962 M $ 11.07 1.61 % $ 3.31 B canadaCanada
Agenus Agenus
AGEN
97.8 M $ 7.08 2.07 % $ 211 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
Amryt Pharma plc Amryt Pharma plc
AMYT
2.55 B - - $ 621 M britainBritain
Evelo Biosciences Evelo Biosciences
EVLO
27 M - -14.46 % $ 27.9 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
427 M - -14.27 % $ 1.7 M singaporeSingapore
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
2.05 B - -15.15 % $ 60.3 M britainBritain
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
252 M $ 5.38 0.28 % $ 285 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
1.63 B $ 33.41 0.16 % $ 1.94 B usaUSA
Adagene Adagene
ADAG
224 M $ 3.3 2.94 % $ 195 M chinaChina
iTeos Therapeutics iTeos Therapeutics
ITOS
293 M - - $ 411 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
3.19 M $ 4.63 21.05 % $ 20 M israelIsrael
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
2.48 B $ 24.7 2.05 % $ 3.75 B usaUSA
Akouos Akouos
AKUS
184 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
548 M - -0.23 % $ 916 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
15.4 M $ 0.07 9.81 % $ 855 K usaUSA
Allakos Allakos
ALLK
114 M - - $ 28.6 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
13 M $ 23.52 458.67 % $ 98.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
26 M - 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
847 M $ 5.13 0.1 % $ 983 M canadaCanada
ADC Therapeutics SA ADC Therapeutics SA
ADCT
139 M $ 1.09 2.35 % $ 139 M schweizSchweiz
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
4.13 M - 17.91 % $ 11.1 M usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
1.31 M $ 5.03 2.65 % $ 3.36 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
3.65 B $ 27.54 0.04 % $ 4.64 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
1.13 M $ 0.22 1.52 % $ 356 K usaUSA
ADMA Biologics ADMA Biologics
ADMA
3.78 B $ 9.18 0.16 % $ 2.19 B usaUSA
Axcella Health Axcella Health
AXLA
25 M - -16.42 % $ 249 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
17 M - 57.95 % $ 12.8 M usaUSA
Atreca Atreca
BCEL
49 M - -11.76 % $ 5.79 M usaUSA
Berkeley Lights Berkeley Lights
BLI
117 M - -7.31 % $ 87 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
78.6 M - -74.18 % $ 955 K usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
126 M $ 7.15 1.27 % $ 312 M usaUSA
Baudax Bio Baudax Bio
BXRX
779 K - 0.59 % $ 63 K usaUSA
Calithera Biosciences Calithera Biosciences
CALA
49.1 M - -10.95 % $ 876 K usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.43 B - - $ 3.45 B usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
243 M - -55.98 % $ 2.15 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
1.88 M - - $ 3.74 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
423 M - - $ 789 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
6.68 B - - $ 7.29 B usaUSA
AC Immune SA AC Immune SA
ACIU
287 M $ 2.67 2.6 % $ 269 M schweizSchweiz
Akebia Therapeutics Akebia Therapeutics
AKBA
334 M $ 1.0 5.6 % $ 257 M usaUSA
Alector Alector
ALEC
247 M $ 2.17 1.64 % $ 224 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
65.9 M $ 5.05 0.96 % $ 49.9 M usaUSA